Patents by Inventor Samuel K. Kulp
Samuel K. Kulp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9174951Abstract: Thiazolidinedione compounds and pharmaceutically acceptable salts thereof are described. The compounds can be used in methods of treating cancer in a subject by administering to the subject a therapeutically effective amount of the compound. The compounds can also be used in methods of inhibiting glucose uptake in a cell by contacting the cell with the compound.Type: GrantFiled: March 28, 2013Date of Patent: November 3, 2015Assignee: OHIO STATE INNOVATION FOUNDATIONInventors: Ching-Shih Chen, Dasheng Wang, Samuel K. Kulp
-
Patent number: 9079899Abstract: A method of treating infection by Staphylococcus in a subject by administering a pharmaceutical composition including a celecoxib derivative of formula I or a pharmaceutically acceptable salt thereof is described. The preparation of numerous celecoxib derivatives for testing as potential anti-staphylococcal agents is also described.Type: GrantFiled: October 31, 2011Date of Patent: July 14, 2015Assignee: THE OHIO STATE UNIVERSITYInventors: Ching-Shih Chen, Hao-Chieh Chiu, Dasheng Wang, Samuel K. Kulp
-
Publication number: 20150051255Abstract: Thiazolidinedione compounds and pharmaceutically acceptable salts thereof are described. The compounds can be used in methods of treating cancer in a subject by administering to the subject a therapeutically effective amount of the compound. The compounds can also be used in methods of inhibiting glucose uptake in a cell by contacting the cell with the compound.Type: ApplicationFiled: March 28, 2013Publication date: February 19, 2015Applicant: The Ohio State University Research FoundationInventors: Ching-Shih Chen, Dasheng Wang, Samuel K. Kulp
-
Patent number: 8658647Abstract: A number of compounds and use of the compounds in a method for treating or preventing cancer in a subject by administering to the subject a pharmaceutical composition including a compound of formula I or a pharmaceutically acceptable salt thereof are described. The compounds can also be used to inhibit integrin-linked kinase in a cell, which has an effect on the Akt signaling pathway.Type: GrantFiled: November 21, 2011Date of Patent: February 25, 2014Assignee: The Ohio State University Research FoundationInventors: Ching-Shih Chen, Su-Lin Lee, Samuel K. Kulp
-
Publication number: 20140031388Abstract: Anticancer compounds according to formula I are described herein. wherein R1, R2, R3 and R4 are selected from H, CH3, OH, SH, OCH3, NHR?, halogen, CF3, N-linked pyrrolidine, and SO2NHR?, or any combination thereof; R5 is an alkyl, alkenyl, or alkaryl group including from 4 to 11 carbons, X is selected from CH2, CHOH, C?O, S?O, O?S?O, and an oxetane ring, Y is selected from CH2, O, and NH, and R? is a H, aryl, or a lower alkyl group, or pharmaceutically acceptable salts thereof. The compounds have been shown to facilitate site-specific dephosphorylation of Akt at Ser-473, thereby inactivating Akt and decreasing dysregulation of Akt signaling that can occur in cancer cells.Type: ApplicationFiled: July 26, 2013Publication date: January 30, 2014Inventors: Ching-Shih Chen, Dasheng Wang, Samuel K. Kulp
-
Publication number: 20130289004Abstract: A method of treating infection by Staphylococcus in a subject by administering a pharmaceutical composition including a celecoxib derivative of formula I or a pharmaceutically acceptable salt thereof is described. The preparation of numerous celecoxib derivatives for testing as potential anti-staphylococcal agents is also described.Type: ApplicationFiled: October 31, 2011Publication date: October 31, 2013Applicant: The Ohio State University Research FoundationInventors: Ching-Shih Chen, Hao-Chieh Chiu, Dasheng Wang, Samuel K. Kulp
-
Patent number: 8461362Abstract: Tocopheryl succinate derivatives according to formula I: are described. These compounds increase the activity of protein phosphatase 2A, can be included in pharmaceutical compositions, and can be used for the treatment of androgen receptor-dependent cancers such as prostate cancer.Type: GrantFiled: April 13, 2010Date of Patent: June 11, 2013Assignee: The Ohio State University Research FoundationInventors: Ching-Shih Chen, Dasheng Wang, Samuel K. Kulp
-
Patent number: 8362071Abstract: Vitamin E succinate derivatives according to formula I: are described. These compounds can be included in pharmaceutical compositions, and can be used for the treatment of cancers such as metastatic cancer and as antiadhesive agents.Type: GrantFiled: April 16, 2010Date of Patent: January 29, 2013Assignee: The Ohio State University Research FoundationInventors: Ching-Shih Chen, Dasheng Wang, Samuel K. Kulp
-
Patent number: 8309768Abstract: A number of FTY720-derived compounds with antitumor activity are described. These compounds include the compounds of formula I: wherein R1 is independently selected from the group consisting of hydrogen, methyl. methoxy, and hydroxyl; R2 is independently selected from the group consisting of hydrogen, methoxy, and hydroxyl; R3 is independently selected from the group consisting of alkyl and cyclo-alkyl; and n is independently selected from 0 to 6. The compounds have lower immunosuppressive side effects as a result of not being phosphorylated by sphingosine kinase 2.Type: GrantFiled: November 29, 2011Date of Patent: November 13, 2012Assignee: The Ohio State University Research FoundationInventors: Ching-Shih Chen, Samuel K. Kulp, Dasheng Wang, John C. Byrd, Natarajan Muthusamy
-
Publication number: 20120142702Abstract: A number of compounds and use of the compounds in a method for treating or preventing cancer in a subject by administering to the subject a pharmaceutical composition including a compound of formula I or a pharmaceutically acceptable salt thereof are described. The compounds can also be used to inhibit integrin-linked kinase in a cell, which has an effect on the Akt signaling pathway.Type: ApplicationFiled: November 21, 2011Publication date: June 7, 2012Applicant: The Ohio State University Research FoundationInventors: Ching-Shih Chen, Su-Lin Lee, Samuel K. Kulp
-
Publication number: 20120136063Abstract: A number of FTY720-derived compounds with antitumor activity are described. These compounds include the compounds of formula I: wherein R1 is independently selected from the group consisting of hydrogen, methyl. methoxy, and hydroxyl; R2 is independently selected from the group consisting of hydrogen, methoxy, and hydroxyl; R3 is independently selected from the group consisting of alkyl and cyclo-alkyl; and n is independently selected from 0 to 6. The compounds have lower immunosuppressive side effects as a result of not being phosphorylated by sphingosine kinase 2.Type: ApplicationFiled: November 29, 2011Publication date: May 31, 2012Applicant: The Ohio State University Research FoundationInventors: Ching-Shih Chen, Samuel K. Kulp, Dasheng Wang, John C. Byrd, Natarajan Muthusamy
-
Publication number: 20120108823Abstract: A series of celecoxib derivatives defined by Formula I: were prepared and evaluated for their ability to inhibit the gram-negative bacteria Francisella tularensis. Pharmaceutical compositions including celecoxib derivatives and their use in methods for treating or preventing infection by Francisella tularensis in a subject are described.Type: ApplicationFiled: April 22, 2009Publication date: May 3, 2012Applicant: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATIONInventors: Ching-Shih Chen, Hao-Shieh Chiu, Samuel K. Kulp
-
Publication number: 20100267820Abstract: Vitamin E succinate derivatives according to formula I: are described. These compounds can be included in pharmaceutical compositions, and can be used for the treatment of cancers such as metastatic cancer and as antiadhesive agents.Type: ApplicationFiled: April 16, 2010Publication date: October 21, 2010Applicant: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATIONInventors: Ching-Shih Chen, Dasheng Wang, Samuel K. Kulp
-
Publication number: 20100267673Abstract: Tocopheryl succinate derivatives according to formula I: are described. These compounds increase the activity of protein phosphatase 2A, can be included in pharmaceutical compositions, and can be used for the treatment of androgen receptor-dependent cancers such as prostate cancer.Type: ApplicationFiled: April 13, 2010Publication date: October 21, 2010Applicant: THE OHIO SATE UNIVERSITY RESEARCH FOUNDATIONInventors: Ching-Shih Chen, Dasheng Wang, Samuel K. Kulp